Literature DB >> 1997945

Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5' cap region.

T A Bacon1, E Wickstrom.   

Abstract

A series of antisense pentadecamers complementary to a variety of target sequences between the cap and AUG initiation codon regions of c-myc mRNA was synthesized and used to treat human promyelocytic leukemia HL-60 cells. The sensitivity of the cap-region sequences to antisense inhibition of c-myc p65 expression was two to three times that of the original initiation codon antisense sequence. The other target sequences downstream of the cap and up to the AUG initiation codon were comparable to the initiation codon sequence, except that the first splice junction was slightly more sensitive. At the primary initiation codon target, a dodecamer was about half as effective as the original pentadecamer, whereas an octadecamer was about twice as effective. The observation of variation in antisense efficacy as a function of target location in c-myc mRNA may represent a combination of the effects of hybrid arrest, RNase H attack, and interference in RNA processing. Alternatively, the most sensitive targets might be those that are the most exposed in the secondary and tertiary structure of c-myc mRNA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997945

Source DB:  PubMed          Journal:  Oncogene Res        ISSN: 0890-6467


  15 in total

Review 1.  Designing antisense to inhibit the renin-angiotensin system.

Authors:  D Mohuczy; M I Phillips
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

2.  Post-transcriptional silencing of Notch2 mRNA in chronic lymphocytic [corrected] leukemic cells of B-CLL patients.

Authors:  Kaneez Fatima; Rehan Zafar Paracha; Ishtiaq Qadri
Journal:  Mol Biol Rep       Date:  2011-12-10       Impact factor: 2.316

3.  Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures.

Authors:  R V Giles; D M Tidd
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

Review 4.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

Review 5.  Oligonucleotide treatment of ras-induced tumors in nude mice.

Authors:  E Wickstrom
Journal:  Mol Biotechnol       Date:  2001-05       Impact factor: 2.695

Review 6.  DNA and RNA derivatives to optimize distribution and delivery.

Authors:  Eric Wickstrom
Journal:  Adv Drug Deliv Rev       Date:  2015-04-22       Impact factor: 15.470

7.  Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices.

Authors:  R A Stull; L A Taylor; F C Szoka
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

8.  A more efficient and specific strategy in the ablation of mRNA in Xenopus laevis using mixtures of antisense oligos.

Authors:  R Morgan; M Edge; A Colman
Journal:  Nucleic Acids Res       Date:  1993-09-25       Impact factor: 16.971

9.  Specific post-transcriptional inhibition of mRNA for ligand binding chain of IgE high affinity receptor.

Authors:  Sobia Rana; Ishrat Waheed; Muhammad Imran
Journal:  Mol Biol Rep       Date:  2009-08-21       Impact factor: 2.316

10.  Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate.

Authors:  Y Huang; R Snyder; M Kligshteyn; E Wickstrom
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.